Pershing Square, Pharma Join To Buy Botox Maker

Apr 22 2014 | 2:03pm ET

For its latest activist effort, Pershing Square Capital Management has already enlisted a buyer.

The New York-based hedge fund and Valeant Pharmaceuticals have joined forces in a hostile bid for Allergan Inc., the pharmaceutical company that makes Botox. Since striking its agreement with Valeant, Pershing Square has bought up some 9.7% of Allergan’s shares.

The deal, for cash and Valeant stock, is worth in excess of $45 billion.

Valeant has been seeking a deal for Allergan for a year, to no avail. The company said the merger would “create an unrivaled platform for growth and value creation in healthcare.”


In Depth

Q&A: Portfolio Advisors' Brian Murphy On The Advantages of A Private Markets Platform

Jan 2 2018 | 11:05am ET

Most private markets firms reference their platforms as a source of competitive...

Lifestyle

CFA Institute To Add Computer Science To Exam Curriculum

May 24 2017 | 9:25pm ET

Starting in 2019, financial industry executives sitting for the coveted Chartered...

Guest Contributor

Steinbrugge: The Top Hedge Fund Industry Trends for 2018

Jan 2 2018 | 12:22pm ET

Each year, Don Steinbrugge’s Agecroft Partners compiles the insights gained...

 

FINalternatives Trending

From the current issue of